Suzhou Xinnowei Medical Technology Co., Ltd. will list and begin trading on the Shanghai Stock Exchange STAR Market on Sept. 16, 2026.

AstraZeneca said a late-stage trial of Etcamah in recurrent or metastatic, treatment‑naive breast cancer patients failed to delay disease progression versus standard therapy. Analysts say the setback could cut the drug’s peak sales by up to $3.8bn. The result raises pressure on CEO Pascal Soriot to prove the company’s internal pipeline. AstraZeneca also reported positive data over the weekend from two lung cancer candidates.

美國國債收益率小幅上升，2年期至10年期收益率創9月11日以來新高。